Your browser doesn't support javascript.
loading
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Bertino, Erin M; Gentzler, Ryan D; Clifford, Sarah; Kolesar, Jill; Muzikansky, Alona; Haura, Eric B; Piotrowska, Zofia; Camidge, D Ross; Stinchcombe, Thomas E; Hann, Christine; Malhotra, Jyoti; Villaruz, Liza C; Paweletz, Cloud P; Lau, Christie L; Sholl, Lynette; Takebe, Naoko; Moscow, Jeffrey A; Shapiro, Geoffrey I; Jänne, Pasi A; Oxnard, Geoffrey R.
Affiliation
  • Bertino EM; The Ohio State University, Columbus, Ohio.
  • Gentzler RD; University of Virginia Cancer Center, Charlottesville, Virginia.
  • Clifford S; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Kolesar J; University of Kentucky, Lexington, Kentucky.
  • Muzikansky A; Massachusetts General Hospital, Boston, Massachusetts.
  • Haura EB; H. Lee Moffitt Cancer Center, Tampa, Florida.
  • Piotrowska Z; Massachusetts General Hospital, Boston, Massachusetts.
  • Camidge DR; University of Colorado Hospital, Aurora, Colorado.
  • Stinchcombe TE; Duke University Medical Center, Durham, North Carolina.
  • Hann C; Johns Hopkins/Sidney Kimmel Cancer Center, Baltimore, Maryland.
  • Malhotra J; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
  • Villaruz LC; University of Pittsburgh UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania.
  • Paweletz CP; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Lau CL; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Sholl L; Brigham and Women's Hospital, Boston, Massachusetts.
  • Takebe N; National Cancer Institute, Bethesda, Maryland.
  • Moscow JA; National Cancer Institute, Bethesda, Maryland.
  • Shapiro GI; Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Jänne PA; Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu.
  • Oxnard GR; Dana-Farber Cancer Institute, Boston, Massachusetts.
Clin Cancer Res ; 27(6): 1604-1611, 2021 03 15.
Article in En | MEDLINE | ID: mdl-33376097
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Year: 2021 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Mutation Type of study: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Year: 2021 Document type: Article